PainReform Ltd. (NASDAQ:PRFX) Short Interest Update

PainReform Ltd. (NASDAQ:PRFX) was the target of a large decline in short interest during the month of April. As of April 30th, there was short interest totalling 19,800 shares, a decline of 63.7% from the April 15th total of 54,600 shares. Based on an average daily volume of 138,900 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.2% of the shares of the company are sold short.

PainReform Price Performance

Shares of NASDAQ:PRFX traded down $0.01 during trading on Friday, reaching $0.80. 2,632 shares of the company’s stock traded hands, compared to its average volume of 106,302. PainReform has a fifty-two week low of $0.69 and a fifty-two week high of $26.41. The company has a 50-day simple moving average of $1.46 and a 200-day simple moving average of $2.01.

Institutional Investors Weigh In On PainReform

A hedge fund recently bought a new stake in PainReform stock. Armistice Capital LLC bought a new position in shares of PainReform Ltd. (NASDAQ:PRFX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 170,000 shares of the company’s stock, valued at approximately $468,000. Armistice Capital LLC owned about 10.90% of PainReform at the end of the most recent reporting period. Institutional investors own 37.28% of the company’s stock.

PainReform Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.